Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Michelle KolbPrakash Satwani

Abstract

Tacrolimus (FK506) is a calcineurin inhibitor and is an essential component of many immunosuppressive regimens. The oral bioavailability of tacrolimus may be affected by many factors, including patient age and gender, as well as by drug-drug interactions or genetic polymorphisms in drug metabolism. The dosing recommendations for pediatric allogeneic hematopoietic cell transplantation (alloHCT) recipients have been derived from tacrolimus use in adult solid-organ transplantation patients. Data describing the impact of conversion of i.v. tacrolimus to oral on the incidence of acute graft-versus-host disease (aGVHD) are limited in children after alloHCT. In this study, we describe the incidence of grades II to IV aGVHD after conversion from i.v. tacrolimus to oral tacrolimus and study the clinical factors associated with delayed achievement of therapeutic blood levels. In this retrospective analysis, 68 pediatric patients (median age, 6.7 years; range, .25 to 22 years), underwent alloHCT for malignant and nonmalignant diseases and received tacrolimus and mycophenolate mofetil for aGVHD prophylaxis. Among all patients, the median number of days to achieve therapeutic tacrolimus trough concentration (10 ng/mL to 20 ng/mL) was 7 days...Continue Reading

References

Oct 21, 2000·Bone Marrow Transplantation·D PrzepiorkaK W Chan
May 19, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Iain A M MacPheeDavid W Holt
Oct 16, 2007·Bone Marrow Transplantation·D A Jacobsohn
Feb 23, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Prakash SatwaniMitchell S Cairo
Dec 17, 2011·Transplantation Proceedings·G CheralaA Al-Uzri
Feb 5, 2013·Transplantation Proceedings·H A ChakkeraL A Frassetto
Mar 8, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kavita RadhakrishnanPrakash Satwani
Oct 7, 2014·Pediatric Transplantation·Nicholas Larkins, Douglas G Matsell
Dec 24, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Katharine OfferPrakash Satwani
May 8, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anya LevinsonPrakash Satwani

❮ Previous
Next ❯

Citations

Feb 18, 2021·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Heather P MayHassan Alkhateeb
Mar 15, 2021·Transplantation Proceedings·Ryohei YamamotoTomonori Habuchi
Jun 30, 2021·Journal of Managed Care & Specialty Pharmacy·Jason T HurwitzDaniel C Malone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Betul OranR E Champlin
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Takehiko MoriShinichiro Okamoto
© 2022 Meta ULC. All rights reserved